Literature DB >> 34146889

Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy.

Linping Zhao1, Rongrong Zheng1, Lingshan Liu2, Xiayun Chen1, Runtian Guan1, Ni Yang3, Ali Chen3, Xiyong Yu4, Hong Cheng5, Shiying Li6.   

Abstract

Amplifying oxidative stress to break intracellular redox homeostasis could accelerate tumor cell death. In this work, a self-delivery oxidative stress amplifier is developed for chemotherapy sensitized immunotherapy. By virtue of the π-π stacking and coordination effect, copper ions (Cu2+), doxorubicin (DOX) and NLG919 are able to self-assembly into the nanosized oxidative stress amplifier (designated as Cu-DON) with a favorable stability and a biocompatibility. Intravenously administrated Cu-DON could effectively accumulate and penetrate into tumor tissues for cellular uptake. Subsequently, the GSH-responsive DOX release will initiate the immunogenic chemotherapy (IC) for primary tumor inhibition. Moreover, Cu2+-mediated GSH consumption and DOX-triggered oxidative stress could cause the intracellular redox imbalance, contributing to immunogenic cell death (ICD) response. Further, the concomitant release of NLG919 would inhibit indoleamine 2,3-dioxygenase 1 (IDO-1) to reverse immunosuppressive tumor microenvironment (ITM) for enhanced immunotherapy. Consequently, this self-delivery oxidative stress amplifier greatly restrains the growth of primary, distant as well as rechallenged tumors by chemotherapy sensitized immunotherapy, which would shed light on the development of combination therapy to block tumor growth and metastasis in clinic.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Immunogenic cell death; Immunotherapy; Oxidative stress; Self-delivery

Mesh:

Substances:

Year:  2021        PMID: 34146889     DOI: 10.1016/j.biomaterials.2021.120970

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

Review 1.  Recent advances in sonodynamic immunotherapy.

Authors:  Hui Wang; Guo-Qing Sui; Zhi-Xia Sun; Jia-Rui Du; Yang Wang; Zong-Hua Yue; Han-Yu Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-13       Impact factor: 4.322

Review 2.  Nanomedicine-enabled chemotherapy-based synergetic cancer treatments.

Authors:  Wencheng Wu; Yinying Pu; Jianlin Shi
Journal:  J Nanobiotechnology       Date:  2022-01-04       Impact factor: 10.435

3.  Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy.

Authors:  Weixi Jiang; Li Chen; Xun Guo; Chen Cheng; Yuanli Luo; Jingxue Wang; Junrui Wang; Yang Liu; Yang Cao; Pan Li; Zhigang Wang; Haitao Ran; Zhiyi Zhou; Jianli Ren
Journal:  Theranostics       Date:  2022-03-21       Impact factor: 11.600

Review 4.  Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy.

Authors:  Jin Zhang; Yandai Lin; Zhe Lin; Qi Wei; Jiaqi Qian; Renjie Ruan; Xiancai Jiang; Linxi Hou; Jibin Song; Jianxun Ding; Huanghao Yang
Journal:  Adv Sci (Weinh)       Date:  2021-12-19       Impact factor: 16.806

Review 5.  Application of nanosonosensitizer materials in cancer sono-dynamic therapy.

Authors:  Chaotao Hu; Biao Hou; Songlin Xie
Journal:  RSC Adv       Date:  2022-08-15       Impact factor: 4.036

6.  Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.

Authors:  Yezi Chen; Xiaoqin Luo; Yun Liu; Yunlei Zou; Shiqi Yang; Chaoqi Liu; Yun Zhao
Journal:  Int J Nanomedicine       Date:  2022-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.